Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Graham on Utilizing Biomarkers to Guide Treatment in Intrahepatic Cholangiocarcinoma

June 29th 2021

Rondell Graham, MBBS, discusses utilizing biomarkers to guide treatment for patients with intrahepatic cholangiocarcinoma.

Nivolumab/Ipilimumab Approved in Europe for dMMR or MSI-H Metastatic Colorectal Cancer

June 29th 2021

The European Commission has approved the combination of nivolumab plus ipilimumab for use in adult patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following previous fluoropyrimidine-based combination chemotherapy.

Pembrolizumab/Chemo Approved in Europe for Select Esophageal Cancer or HER2– GEJ Adenocarcinoma

June 29th 2021

The European Commission has approved pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative gastroesophageal junction adenocarcinoma whose tumors have PD-L1 expression.

Frontline Cabozantinib Plus Atezolizumab Significantly Improves PFS in Advanced HCC

June 28th 2021

The combination of cabozantinib and atezolizumab was found to significantly improve progression-free survival compared with sorafenib when used in the first-line treatment of patients with advanced hepatocellular carcinoma, meeting a primary end point of the phase 3 COSMIC-312 trial.

Modified FOLFIRINOX Demonstrates Efficacy in Advanced Gallbladder Cancer

June 28th 2021

Modified fluorouracil, oxaliplatin, and irinotecan elicited encouraging responses and an acceptable toxicity profile as a frontline treatment for patients with unresectable gallbladder cancer

EU Panel Recommends Adjuvant Nivolumab for Select Esophageal, GEJ Cancers

June 25th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after previous neoadjuvant chemoradiotherapy.

Frontline Sintilimab Plus Chemo Improves OS in Esophageal Squamous Cell Carcinoma

June 25th 2021

The addition of sintilimab to chemotherapy significantly improved overall survival over chemotherapy alone when used as a first-line treatment in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma, meeting the primary end point of the phase 3 ORIENT-15 trial.

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

June 24th 2021

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Rapid Readouts: Final Results from Phase 3 ClarIDHy Trial

June 24th 2021

Ghassan K. Abou-Alfa, MD, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding final results from the ClarIDHy trial. In the phase 3 study, investigators examined ivosidenib vs placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation.

Dr. Sonbol on the Role of Pembrolizumab in Gastric Cancer

June 24th 2021

Bassam Sonbol, MD, discusses the role of pembrolizumab in the treatment of patients with gastric cancer.

Dr. Ahn on Navigating Among Available Therapeutic Options in Advanced, Unresectable HCC

June 22nd 2021

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Dr. Ahn on Treatment Considerations With Atezolizumab/Bevacizumab in Unresectable HCC

June 21st 2021

Daniel H. Ahn, DO, discusses considerations for treatment with atezolizumab and bevacizumab in patients with hepatocellular carcinoma.

Treatment Strategies in HER2+ Gastrointestinal Malignancies

June 21st 2021

This article discusses case studies and treatment strategies in HER2-postive gastrointestinal malignancies, and features insights from experts John Marshall, MD, Yelena Y Janjigian, MD, Melissa Lumish, MD, Daniel Catenacci, MD, Carolina Soto Chervin, MD, PhD, Wells Messersmith, MD, Robert Lentz, MD, Zev Wainberg, MD, and Vina Pulido Nguyen, MD. Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.

Surufatinib Approved in China for Advanced Pancreatic Neuroendocrine Tumors

June 18th 2021

The National Medical Products Administration of China has approved surufatinib for the treatment of patients with advanced pancreatic neuroendocrine tumors.

Dr. Ahn on the Utility of Atezolizumab/Bevacizumab in HCC

June 17th 2021

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

FDA Grants Orphan Drug Designation to Gunagratinib for Cholangiocarcinoma

June 17th 2021

The FDA has granted an orphan drug designation to gunagratinib as a potential therapeutic option for patients with cholangiocarcinoma.

George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline

June 17th 2021

Dr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.

Dr. Charlton on the Interaction Between Liver Disease and HCC

June 16th 2021

Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.

Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer

June 14th 2021

Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.

Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric Cancer

June 14th 2021

Katelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.